Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karen, S King"'
Autor:
Susan L. Ford, Laura R. Parham, William Spreen, Yu Lou, Kalpana Bakshi, Karen S. King, Kenneth Sutton, David A. Margolis, Parul Patel, Arlene R Hughes, Zhengyu Xue
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily metabolized by uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A1, a known poly
Autor:
Jeff Legos, Bijoyesh Mookerjee, Kijoung Song, Colin F. Spraggs, Diptee A. Kulkarni, Linda Briley, Christine Dabrowski, Karen S. King
Publikováno v:
Pharmacogenomics. 17:459-462
Aim: Pyrexia is a common adverse event (AE) on dabrafenib treatment (monotherapy or combination with trametinib). Since germline SNPs and HLA alleles are implicated in drug-induced AEs, this study investigated their association with pyrexia. Patients
Autor:
Linda P. Briley, Lini Pandite, Dana Fraser, Karen S. King, Xiaojing Wang, Sandy Stinnett, Colin F Spraggs, Alan P. Graves, Andreas du Bois, Hiroomi Tada, Ionel Mitrica, Matthew R. Nelson, Neil Kaplowitz, Zhengyu Xue, Thomas Powles, Liling Warren, Christopher L. Carpenter, Toby Johnson, Chun-Fang Xu
Publikováno v:
Clin Cancer Res
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Autor:
F. Forget, Michael Friedlander, Sandy Stinnett, Claudio Zamagni, Karen S. King, Martin Imhof, Sang Yoon Park, Dearbhaile E. O’Donnell, Chun Fang Xu, Dominique Berton-Rigaud, Philipp Harter, Toby Johnson, John K. Chan, Nicoletta Colombo, Andreas du Bois, Florian Heitz, Mansoor Raza Mirza, Catherine Barrett, Muneaki Shimada, Thomas J. Herzog, Josep M. del Campo, Minesh Jobanputra
Publikováno v:
Gynecologic oncology. 140(3)
Objective AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the